| Balance Sheets | 2025-09-30 | |||
|---|---|---|---|---|
| Cash in bank | 2,722,451 | |||
| Prepaid expenses | 90,643 | |||
| Vat receivable | 44,043 | |||
| Inventories | 1,075 | |||
| Total current assets | 2,858,212 | |||
| Fixed assets, net | 51,407 | |||
| Intangible assets, net | 2,093,228 | |||
| Total long-term assets | 2,144,635 | |||
| Total assets | 5,002,847 | |||
| Notes payable, net | 3,156,052 | |||
| Derivative liabilities | 3,656,394 | |||
| Loans payable, related parties | 841,548 | |||
| Accounts payable | 1,641,443 | |||
| Accrued liabilities | 407,975 | |||
| Total current liabilities | 9,703,412 | |||
| Total liabilities | 9,703,412 | |||
| Preferred stock, value | 0 | |||
| Preferred stock, value-Preferred Stock | 0 | |||
| Preferred stock, value-Series BConvertible Preferred Stock | 0 | |||
| Preferred stock, value-Series CConvertible Preferred Stock | 0 | |||
| Preferred stock, value-Series DConvertible Preferred Stock | 0 | |||
| Preferred stock, value-Series C1Convertible Preferred Stock | 1 | |||
| Common stock, 0.0001 par value, respectively 100,000,000 authorized 1,934,878 and 5,800,000 shares issued outstanding | 195 | |||
| Additional paid in capital | 6,845,036 | |||
| Foreign currency translation adjustment | -221,172 | |||
| Accumulated deficit | -11,324,625 | |||
| Total stockholders deficit | -4,700,565 | |||
| Total liabilities and stockholders deficit | 5,002,847 | |||
Protagenic Therapeutics, Inc. new (PTIXW)
Protagenic Therapeutics, Inc. new (PTIXW)